3-bromo-2-oxopropionate-1-propyl-ester and Leukemia

3-bromo-2-oxopropionate-1-propyl-ester has been researched along with Leukemia* in 1 studies

Other Studies

1 other study(ies) available for 3-bromo-2-oxopropionate-1-propyl-ester and Leukemia

ArticleYear
Targeting glycolysis in leukemia: a novel inhibitor 3-BrOP in combination with rapamycin.
    Leukemia research, 2011, Volume: 35, Issue:6

    Rapidly proliferating solid tumor cells are often dependent on glycolysis for ATP production even in normoxia (the Warburg effect), however it is not yet clear whether acute leukemias have a similarly increased dependence on aerobic glycolysis. We report that all acute leukemia subtypes (pre-B ALL, T-ALL and AML) demonstrated growth arrest and cell death when treated the novel glycolysis inhibitor 3-BrOP. Potentiated ATP depletion and pro-apoptotic effects were seen for 3-BrOP combinations with the cytochrome-c-reductase inhibitor antimycin A and the mTOR inhibitor rapamycin. These results reveal a potential role for glycolysis inhibition in acute leukemia subtypes and suggest potential combinations.

    Topics: Acute Disease; Adenosine Triphosphate; Antimycin A; Apoptosis; Caspase 3; Cell Line; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Synergism; Glycolysis; HL-60 Cells; Humans; Hydrocarbons, Brominated; Immunoblotting; Jurkat Cells; Leukemia; Propionates; Sirolimus; Time Factors; U937 Cells

2011
chemdatabank.com